The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2016
Filed:
Sep. 03, 2014
Applicant:
Glaxosmithkline Intellectual Property (No. 2) Limited, Brentford, GB;
Inventors:
Neil W. Johnson, Collegeville, PA (US);
Jiri Kasparec, Collegeville, PA (US);
Meagan B. Rouse, Collegeville, PA (US);
Xinrong Tian, Collegeville, PA (US);
William Henry Miller, Collegeville, PA (US);
Dominic Suarez, Collegeville, PA (US);
Assignee:
GlaxoSmithKline Intellectual Property (No. 2) Limited, Brentford, Middlesex, GB;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 211/35 (2006.01); C07D 211/62 (2006.01); C07D 211/26 (2006.01); C07F 9/59 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); C07D 413/06 (2006.01); C07D 265/30 (2006.01); C07D 207/09 (2006.01); C07D 211/96 (2006.01); C07D 223/04 (2006.01); C07C 271/24 (2006.01); C07C 211/36 (2006.01); C07F 5/02 (2006.01); C07D 401/12 (2006.01);
U.S. Cl.
CPC ...
C07F 9/591 (2013.01); C07C 211/35 (2013.01); C07C 211/36 (2013.01); C07C 271/24 (2013.01); C07D 207/09 (2013.01); C07D 211/26 (2013.01); C07D 211/62 (2013.01); C07D 211/96 (2013.01); C07D 223/04 (2013.01); C07D 265/30 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 413/06 (2013.01); C07F 5/02 (2013.01); C07F 5/025 (2013.01); C07C 2101/02 (2013.01); C07C 2101/14 (2013.01);
Abstract
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.